Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1b Single Ascending and Multiple Dose First-in-man Study in Adult Patients With Non-transfusion-dependent Beta-thalassaemia or Low Risk Myelodysplastic Syndrome to Investigate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of SLN124

Next Previous
Trial Profile

Phase 1b Single Ascending and Multiple Dose First-in-man Study in Adult Patients With Non-transfusion-dependent Beta-thalassaemia or Low Risk Myelodysplastic Syndrome to Investigate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of SLN124

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 23 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Divesiran (Primary)
  • Indications Beta-thalassaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; First in man
  • Sponsors Silence Therapeutics

Most Recent Events

  • 16 May 2022 According to a Silence Therapeutics media release, topline data in the SLN124 phase 1b single-ascending dose study in thalassemia patients expected in the third quarter of 2022.
  • 23 Apr 2020 Status changed from recruiting to withdrawn prior to enrolment.
  • 25 Mar 2020 According to a Silence Therapeutics media release, in view of the COVID-19 outbreak the company has decided to pause the enrollment in the trial under the current protocol. The Company will recommence patient recruitment under a new and broader protocol when appropriate and interim data from the trial is expected in the first half of 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top